Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Fed’s Dovish Tone Sends Dollar Lower as Markets Price In More Rate Cuts 
Global Markets Slide as Tech Stocks Sink, Yields Rise, and AI Concerns Deepen 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
Mexico Moves to Increase Tariffs on Asian Imports to Protect Domestic Industries 
Brazil Holds Selic Rate at 15% as Inflation Expectations Stay Elevated 
US Signals Openness to New Trade Deal as Brazil Shows Willingness, Says USTR Greer 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Australia’s Labour Market Weakens as November Employment Drops Sharply 
Oil Prices Rebound in Asia as Venezuela Sanctions Risks Offset Ukraine Peace Hopes 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Nvidia Develops New Location-Verification Technology for AI Chips 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
Medipost Co. Ltd, a South Korean biotechnology company, purchased a stake in Canada's OmniaBio Inc., a subsidiary of the Centre for Commercialization of Regenerative Medicine (CCRM), as it is planning to launch its own contract development and manufacturing organization (CDMO) business in North America.
Medipost Co. is planning to make new stem cell treatment products at OmniaBio's facilities in Canada. Thus, it entered into a strategic agreement with the company that is currently a leader in stem cell therapeutics in the world.
The Korean firm engages in the development and manufacturing of stem cell biotech products, and it has acquired a 39.6% stake in OmniaBio Inc. Mediapost is putting in an investment of ₩29.5 billion or around $30 million in Canadian dollars for the purchase. The acquisition deal is set to close on July 1.
According to The Korea Economic Daily, Medipost will be establishing its CDMO business in North America after the deal is completed. It is also planning to raise its stake in OmniaBio by buying convertible bonds worth ₩59.1 billion, and the company is hoping to achieve this by the end of 2024.
With the given numbers, Medipost is set to become the Canadian CDMO firm's largest shareholder, with the total investment reaching C$90 million. OmniaBio's facility is located in Hamilton, Ontario, and it is currently working on a project to expand its facilities for cell and gene therapies from 8,500 square meters to 10,000 square meters site by the year 2025.
"CCRM has spent a great deal of time looking for the right investment partner for OmniaBio, and we are very pleased to have Medipost on board," OmniBio's president, Mitchel Sivilotti, said in a press release. "Medipost will be an initial anchor and revenue generating customer of OmniaBio and will also help us develop an international customer base in Asia. We are launching from a strong and stable position and will be starting construction at McMaster Innovation Park this summer."
Finally, it was revealed that the money from Medipost's purchase deal will be used for the real estate construction and operation of OmniaBio. The overall project was said to be worth $580 million.
